Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

GENZYME ACQUIRES 4% STAKE IN UNIVAX BIOLOGICS under an R&D/marketing collaboration for treatments of cystic fibrosis- related infections, Genzyme reported Aug. 12. Genzyme is to receive worldwide marketing rights to Univax' immune globulin HyperGAM+ CF, which is being developed for the treatment of cystic fibrosis-related Pseudomonas aeruginosa infections. Genzyme has made an initial equity investment of $5 mil. in the Rockville, Md.-based R&D firm and has agreed to pay up to $6 mil. in milestone and licensing fees. In addition, Genzyme will finance two thirds of the estimated $11 mil. in development costs for the biologic. A portion of Genzyme's payments will be made through Neozyme II, a spin-off of the firm formed in March 1992 to finance R&D of Genzyme's gene therapy and protein replacement treatments for cystic fibrosis ("The Pink Sheet" March 30, 1992, T&G-9). Genzyme's gene therapy protocol is underway, having received FDA clearance July 14. NIH's Recombinant DNA Advisory Committee approved the protocol last December ("The Pink Sheet" Dec. 7, 1992, p. 15). Univax will develop and manufacture HyperGAM+ CF, which is expected to enter a Phase I/II trial in cystic fibrosis patients in early 1994. To produce HyperGAM+ CF, plasma donors are inoculated with a vaccine prepared by Univax. Anti-Pseudomonas antibodies from the donors are then extracted and purified to form HyperGAM+ CF. In a Phase I/II clinical trial of the vaccine, the preparation was "shown to be well-tolerated and to elicit the production, within these donors, of polyclonal antibodies against Pseudomonas," Univax said. The firm plans eventually to submit simultaneous PLAs for the vaccine, as used to elicit an immune response in donors, and for the IVIG treatment itself. "Up to 90% of CF patients eventually experience obstructive bronchitis (inflammation of the airways) associated with this bacteria," Genzyme asserted, noting that "in many of these cases, the immediate cause of death is pulmonary failure associated with Pseudomonas infection." HyperGAM+ CF has been granted an orphan designation by the FDA. Univax said that, in light of the collaboration with Genzyme, it will "very likely mutually terminate" a previous agreement with the Cystic Fibrosis Foundation under which the foundation partially funded development of HyperGAM+ CF. The Univax/Genzyme agreement extends to 10 years after the commercialization date of HyperGAM+ CF, at which time it is renewable.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts